DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Merestinib is an investigational drug.
There have been 8 clinical trials for Merestinib. The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2016.
The most common disease conditions in clinical trials are Neoplasm Metastasis, Neoplasms, and Neoplasms, Second Primary. The leading clinical trial sponsors are Eli Lilly and Company, University of Utah, and Jacqueline Garcia, MD.
There are four US patents protecting this investigational drug and fifty-one international patents.
Recent Clinical Trials for Merestinib
|Merestinib on Bone Metastases in Subjects With Breast Cancer||Eli Lilly and Company||Phase 1|
|Merestinib on Bone Metastases in Subjects With Breast Cancer||University of Utah||Phase 1|
|Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia||Eli Lilly and Company||Phase 1|
Top disease conditions for Merestinib
Top clinical trial sponsors for Merestinib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Merestinib||See Pricing||Methods of treating a neuroendocrine tumor||SCRIPPS HEALTH (San Diego, CA)||See Pricing|
|Merestinib||See Pricing||Amidophenoxyindazoles useful as inhibitors of c-Met||Eli Lilly and Company (Indianapolis, IN)||See Pricing|
|Merestinib||See Pricing||Anti-c-Met antibodies||Eli Lilly and Company (Indianapolis, IN)||See Pricing|
|Merestinib||See Pricing||Anti-c-met antibodies||Eli Lilly and Company (Indianapolis, IN)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Merestinib||World Intellectual Property Organization (WIPO)||2019040497||2037-08-22||See Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|